臨床泌尿器科70巻7号

2016年06月発行

特集 進行期精巣腫瘍の診療─難治症例に挑む

〈導入化学療法で寛解が得られない症例への対処〉

二次以降の標準量化学療法

著者： 中村晃和¹ 浮村理¹

所属機関： ¹京都府立医科大学大学院医学研究科泌尿器外科学

ページ範囲：P.500 - P.504

文献概要

▶ポイント

・標準量の一次救済化学療法（二次化学療法）として，RCTはなく確固たるエビデンスのあるものではないが，TIP療法が普及してきている．

・二次救済化学療法（三次化学療法）以降ではさらにエビデンスは少ないが，ゲムシタビンやイリノテカンなどがシスプラチン誘導体とともに使用されており，ある程度の効果が認められる．

・症例が少ないなか，本邦でもさまざまな努力がなされており，日本式の逐次的化学療法の確立が模索されている．

参考文献

1） Nakamura T, Ueda T, Oishi M, et al : Importance of continuous sequential chemotherapy and multimodal treatment for advanced testicular cancer : a high-volume Japanese center experience. Medicine （Baltimore） 94 : e653, 2015

2） IGCCCG International Germ cell consensus classification : a prognostic factor-based staging system for metastatic germ cell cancer. J Clin Oncol 15 : 594─603, 1997

3） Motzer RJ, Geller NL, Tan CC, et al : Salvagechemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience （1979-1989）. Cancer 67 : 1305─1310, 1991

4） Fossa SD, Stenning SP, Gerl A, et al : Prognostic factors in patients progressing after cisplatinbased chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer 80 : 1392─1399, 1999

5） International Prognostic Factors Study Group : Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol 28 : 4906─4911, 2010

6） European Urological Association. Giudelines on Testicular Cancer 2015　http://uroweb.org/wp-content/uploads/11-Testicular-Cancer_LR1.pdf

7） Motzer RJ, Nichols CJ, Margolin KA, et al : Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 25 : 247─256, 2007

8） Ishioka J, Kageyama Y, Ichiyanagi N, et al : Incorporation of TIP （paclitaxel, ifosfamide, cisplatin） into first-line therapy for intermediate to poor risk testicular germ cell tumors with unfavorable marker decline after initial two cycles chemotherapy : a report of three cases. Int J Urol 14 : 455─457, 2007

9） Kurobe M, Kawai K, Oikawa T, et al : Paclitaxel, ifosfamide, and cisplatin （TIP） as salvage and consolidation chemotherapy for advanced germ cell tumor. J Cancer Res Clin Oncol 141 : 127─133, 2015

10） McCaffrey JA, Mazumdar M, Bajorin DF, et al : Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors : Response and survival. J Clin Oncol 15 : 2559─2563, 1997

11） Loehrer PJ Sr, Gonin R, Nichols CR, et al : Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 16 : 2500─2504, 1998

12） Motzer RJ, Sheinfeld J, Mazumdar M, et al : Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 18 : 2413─2418, 2000

13） Mead GM, Cullen MH, Huddart R, et al : A phase II trial of TIP （paclitaxel, ifosfamide and cisplatin） given as second-line （post-BEP） salvage chemotherapy for patients with metastatic germ cell cancer : a medical research council trial. Br J Cancer 93 : 178─184, 2005

14） Fizazi K, Gravis G, Flechon A, et al : Combining gemcitabine, cisplatin, and ifosfamide （GIP） is active in patients with relapsed metastatic germ-cell tumors （GCT）: a prospective multicenter GETUG phase II trial. Ann Oncol 25 : 987─991, 2014

15） Nakamura T, Ueda T, Oishi M, et al : Salvage combined chemotherapy with paclitaxel, ifosfamide and nedaplatin for patients with advanced germ cell tumors. Int J Urol 22 : 288─293, 2015

16） Kollmannsberger C, Beyer J, Liersch R, et al : Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer : a study of the German Testicular Cancer Study Group. J Clin Oncol 22 : 108─114, 2004

17） Bokemeyer C, Oechsle K, Honecker F, et al : Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors : a study of the German Testicular Cancer Study Group. Ann Oncol 19 : 448─453, 2008

18） Necchi A, Nicolai N, Mariani L, et al : Combination of paclitaxel, cisplatin, and gemcitabine （TPG） for multiple relapses or platinum-resistant germ cell tumors : long-term outcomes. Clin Genitourin Cancer 12 : 63─69, 2004

19） Miki T, Mizutani Y, Nonomura N, et al : Irinotecan plus cisplatin has substantial antitumor effect as salvage chemotherapy against germ cell tumors. Cancer 95 : 1879─1885, 2002

20） Pectasides D, Pectasides M, Farmakis D, et al : Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor patients : a phase II study. Eur Urol 46 : 216─221, 2004

21） Nishikawa M, Miyake H and Fujisawa M : Irinotecan and nedaplatin as salvage therapy for patients with advanced germ cell tumors following intensive treatment with cisplatin-based combination chemotherapies. Int J Clin Oncol 21 : 162─167, 2016

22） Shamash J, Powles T, Mutsvangwa K, et al : A phase II study using a topoisomerase I-based approach in patients with multiply relapsed germ-cell tumours. Ann Oncol 18 : 925─930, 2007

23） Yamada S, Saito H, Ohara S, et al : Salvage chemotherapy with docetaxel, ifosfamide and nedaplatin （DIN） for patients with advanced germ cell tumors : a preliminary report. Jpn J Clin Oncol 43 : 734─739, 2013

24） Shiraishi T, Nakamura T, Mikami K, et al : Salvage chemotherapy with paclitaxel and gemcitabine plus nedaplatin （TGN） as part of multidisciplinary therapy in patients with heavily pretreated cisplatin-refractory germ cell tumors. Int J Clin Oncol 14 : 436─441, 2009